Hvad er Org-nummeret på Abarceo Pharma AB?

Abarceo Pharma AB er registreret hos Bolagsverket / SCB under Org 5591397160.

Hvad er omsætningen for Abarceo Pharma AB?

Abarceo Pharma AB rapporterede en omsætning på SEK 4,9M i 2024.

Abarceo Pharma AB beskæftiger 5 personer pr. seneste årsrapport.

Johan Adam Patrik Bruce er administrerende direktør i Abarceo Pharma AB, i rollen siden 2024.

Per Gunnar Ernst Aniansson er bestyrelsesformand i Abarceo Pharma AB, i rollen siden 2025.

Abarceo Pharma ABs registrerede adresse er Per Albin Hanssons Väg 41.

ABActive

Org 5591397160Per Albin Hanssons Väg 41, 214 32 MalmöResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2017 · 8 years old5 employees

Aktivt ansatte i selskabet

Name	Role	Member since
Current (2)
JA Johan Adam Patrik Bruce Chief Executive Officer	Chief Executive Officer	2024
ÅC Åsa Cecilia Andersson Eneberg Chief Auditor	Chief Auditor	2022
Former (2)
KJ Karin Jeanette Roosberg Chief Auditor	Chief Auditor	2020 – 2022
KA Kristian Adolfsen Chief Executive Officer	Chief Executive Officer	2021 – 2024

Ikke-udøvende tilsyn

Name	Role	Member since
Current (5)
SU Siegfried Ulrich Koch Board of Directors	Board of Directors	2021
TR Tara Renée Heitner Hansen Board of Directors	Board of Directors	2025
PG Per Gunnar Ernst Aniansson Chairman	Chairman	2025
CW Claes Wollheim Board of Directors	Board of Directors	2022
CT Claes Tomas Post Board of Directors	Board of Directors	2024
Former (6)
AG Annie George Chandy Chairman	Chairman	2020 – 2021
MK Mathias Kroll Board of Directors	Board of Directors	2020 – 2021
TH Tara Heitner Hansen Board of Directors	Board of Directors	2021 – 2022
MZ Milan Zdravkovic Board of Directors	Board of Directors	2022 – 2022
HM Helen Monika Pettersson Board of Directors	Board of Directors	2020 – 2025
SA Sebastian Albert Ali Salehi Board of Directors	Board of Directors	2020 – 2022

Pr. seneste årsrapport

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.